Dimension Therapeutics, Inc. (DMTX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Dimension Therapeutics, Inc. (DMTX) with AI Score 60/100 (Hold). Dimension Therapeutics, Inc. was a biopharmaceutical company focused on developing and delivering novel gene therapies for patients with rare diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Dimension Therapeutics, Inc. (DMTX) Healthcare & Pipeline Overview
Dimension Therapeutics, Inc. (DMTX) was a gene therapy company targeting rare diseases with a focus on liver-directed therapies. Though once promising, the company is no longer operational, rendering its historical financial data and development pipeline irrelevant for current investment considerations. The company's stock is no longer actively traded.
Investment Thesis
Given that Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. in November 2017 and no longer exists as an independent entity, there is no active investment thesis to evaluate. Historical data indicates that the company was focused on developing gene therapies for rare diseases, particularly liver-directed treatments. At the time, potential value drivers included the advancement of their clinical programs, regulatory milestones, and successful commercialization of gene therapies. However, these factors are no longer relevant as the company is defunct. Investors interested in similar therapeutic areas should focus on Ultragenyx (RARE) or other companies actively developing gene therapies.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin was 100.0% indicating that the cost of goods sold was negligible compared to revenue, though the company's overall profitability was significantly impacted by high research and development expenses.
- Profit Margin was -427.2% reflecting substantial net losses due to the high costs associated with clinical trials and drug development.
- Beta of 4.18 indicating that the stock was highly volatile relative to the market, suggesting higher risk and potential reward (though this is no longer relevant as the company is defunct).
- The company did not pay any dividends, consistent with growth-stage biopharmaceutical companies that typically reinvest earnings into research and development.
- P/E Ratio was -3.04 reflecting the company's negative earnings, a common characteristic of biotech firms investing heavily in R&D before achieving profitability.
Competitors & Peers
Strengths
- Proprietary AAV vector technology.
- Focus on liver-directed gene therapy.
- Expertise in rare disease drug development.
Weaknesses
- High R&D costs.
- Regulatory hurdles for gene therapy products.
- Competition from larger pharmaceutical companies.
Catalysts
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing or upcoming catalysts.
Risks
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing or potential risks.
Growth Opportunities
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
- N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
Opportunities
- Expanding gene therapy applications to new diseases.
- Partnering with larger pharmaceutical companies.
- Securing regulatory approvals for gene therapy products.
Threats
- Clinical trial failures.
- Adverse events associated with gene therapy.
- Competition from alternative therapies.
Competitive Advantages
- Proprietary AAV vector technology for liver-directed gene therapy.
- Patent protection for gene therapy products and methods.
- Expertise in gene therapy development and manufacturing.
- First-mover advantage in specific rare disease indications.
About DMTX
Dimension Therapeutics, Inc., founded with the goal of developing innovative gene therapies, focused on addressing unmet needs in rare genetic diseases. The company's strategy centered around adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to the liver, aiming for long-lasting treatment effects. Dimension Therapeutics pursued programs targeting hemophilia and other inherited metabolic disorders. Their approach involved advanced vector engineering and manufacturing processes to enhance safety and efficacy. Dimension Therapeutics, Inc. was acquired in November 2017 by Ultragenyx Pharmaceutical Inc. After the acquisition, Dimension Therapeutics, Inc. ceased to exist as an independent entity. The company's assets and programs were integrated into Ultragenyx's broader rare disease portfolio. Dimension Therapeutics, Inc. is no longer operational, and its stock is no longer actively traded.
What They Do
- Developed gene therapies for rare diseases.
- Focused on liver-directed gene therapy using AAV vectors.
- Targeted hemophilia and other inherited metabolic disorders.
- Engineered advanced viral vectors for gene delivery.
- Conducted preclinical and clinical trials to evaluate safety and efficacy.
- Sought regulatory approval for their gene therapy products.
- Aimed to provide long-lasting therapeutic effects with single-dose treatments.
Business Model
- Focused on research and development of gene therapies.
- Out-licensed or partnered to commercialize therapies.
- Generated revenue through milestone payments and royalties.
- Sought funding through venture capital and public offerings.
Industry Context
Dimension Therapeutics, Inc. operated within the biopharmaceutical industry, specifically focusing on gene therapy for rare diseases. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying to develop innovative treatments for unmet medical needs. The gene therapy market is projected to experience substantial growth, driven by technological advancements and increasing investment in personalized medicine. Dimension Therapeutics aimed to capitalize on this trend with its liver-directed gene therapy platform before its acquisition.
Key Customers
- Patients with rare genetic diseases.
- Healthcare providers specializing in genetic disorders.
- Pharmaceutical companies interested in gene therapy collaborations.
- Payers (insurance companies and government healthcare systems).
Financials
Chart & Info
Dimension Therapeutics, Inc. (DMTX) stock price: Price data unavailable
Latest News
No recent news available for DMTX.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DMTX.
Price Targets
Wall Street price target analysis for DMTX.
MoonshotScore
What does this score mean?
The MoonshotScore rates DMTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Dimension Therapeutics, Inc. Stock: Key Questions Answered
What does Dimension Therapeutics, Inc. do?
Dimension Therapeutics, Inc. was a biopharmaceutical company focused on developing gene therapies for rare genetic diseases, particularly those affecting the liver. Their approach involved using adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to liver cells, aiming for long-term correction of the underlying genetic defects. The company's goal was to create single-dose treatments that could significantly improve the lives of patients with limited or no existing treatment options. However, Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. in November 2017 and no longer operates independently.
What do analysts say about DMTX stock?
Given that Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. in November 2017 and is no longer a publicly traded entity, there are no current analyst ratings or price targets for DMTX stock. Historical analyst opinions prior to the acquisition may have reflected the potential of the company's gene therapy pipeline and the market opportunity for rare disease treatments. However, these past analyses are no longer relevant for investment decisions, as the company's assets and programs are now part of Ultragenyx's portfolio.
What are the main risks for DMTX?
Since Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. and no longer exists as an independent entity, there are no current risks associated with investing in DMTX. Historically, as a gene therapy company, Dimension Therapeutics faced typical risks associated with the biotechnology industry, including clinical trial failures, regulatory hurdles, competition from other companies developing similar therapies, and the high cost of research and development. However, these risks are no longer applicable to DMTX as a standalone entity.
What are the key factors to evaluate for DMTX?
Dimension Therapeutics, Inc. (DMTX) currently holds an AI score of 60/100, indicating moderate score. Key strength: Proprietary AAV vector technology.. Primary risk to monitor: N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing or potential risks.. This is not financial advice.
How frequently does DMTX data refresh on this page?
DMTX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DMTX's recent stock price performance?
Recent price movement in Dimension Therapeutics, Inc. (DMTX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary AAV vector technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DMTX overvalued or undervalued right now?
Determining whether Dimension Therapeutics, Inc. (DMTX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DMTX?
Before investing in Dimension Therapeutics, Inc. (DMTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. in November 2017 and no longer exists as an independent entity. All information presented is historical and should not be used for current investment decisions.